Hypoxia-inducible factor-1α (HIF-1α), a pivotal regulator, emerges as a potential therapeutic target by orchestrating immunometabolic homeostasis, suppressing fibrosis, preserving gut microbiota balance, and retaining graft-versus-leukemia (GVL) effects. This evidence concerns the gene HIF1A and leukemia.